Robo.ai Inc. will execute a 1-for-25 reverse stock split of its Class A and B shares effective November 6, 2026, to meet Nasdaq's minimum $1.00 bid price requirement. This move will reduce the number of shares but is expected to proportionally increase the trading price, though no guarantee exists that the price will meet the exact multiple. The reverse split will not involve new financing, and the company plans to explore alternative funding methods to support growth while minimizing dilution. Shareholders' percentage ownership and voting rights will remain unchanged aside from fractional share adjustments.
Robo.ai Inc. announces a reverse stock split planned for November 6, 2026. For readers following Technology-sector stocks, here is Pluang's market snapshot as of Nov 04, 2026 03:41 WIB: out of 150 priced stocks, 94 rose and 53 fell. Notable movers include AEHR at USD 63.81 with a 23.98% increase, CIFR at USD 8.07 up 17.64%, and CORZ at USD 14.15 rising 13.15%.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
